Comparative evaluation of diagnosis of ischemic heart disease by high-sensitivity quantification of cardiac biomarkers

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032549

Enrollment

Unknown

Registered

2020-05-02

Start date

2017-12-07

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic heart disease

Interventions

Gold Standard:Quantification of Myo, cTnI and CK-MB by chemiluminescence immunoassay, combine with medical history and electrocardiogram result

Index test:Myo,&#32

cTnI&#32

and&#32

CK-MB&#32

disposable&#32

strips&#32

a&#32

immunofluorescence&#32

reader

Eligibility

Sex/Gender

All

Age

15 Years to 96 Years

Inclusion criteria

Inclusion criteria: 1. Patients from the Emergency Department of Shenzhen Second Peoples Hospital between December 2017 and March 2018 2. Patients receive Myo, cTnI, CK-MB assessment by chemiluminescence immunoassay 3. Patients (or legal guardians) understand the study requirements and are able to provide written informed consents

Exclusion criteria

Exclusion criteria: 1. had received medical treatment before blood collection; 2. were without complete data; 3. had too little sample to perform the test; 4. had hymolysis sample.

Design outcomes

Secondary

Measure	Time frame
age;gender;	—

Primary

Measure	Time frame
CK-MB;cTnI;Myo;	—

Countries

China

Contacts

Public ContactNi Xie

Shenzhen Second People's Hospital

xn100@szu.edu.cn+86 13501580802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026